From Acting Up to Acts of Congress, AIDS Activist Reviews and Critiques a Decade of Social Change Green light, red light at FDA At last month's 4th International Congress on Drug Therapy in HIV Infection (Glasgow, Scotland, U.K.), TAG's Mark…
Deluge of Mutant Coreceptor Discoveries Pave Way for Therapeutic Advances in HIV, Allergy, Arthritis 'Steady stream of papers' With the identification of naturally occurring genetic mutations that can protect against HIV infection and disease progression, academic scientists and pharmaceutical company…
Dutch, U.S. Researchers Report Partial Success with Flushing Strategies; Plan to Suspend Treatment in Patients Halls abuzz with the 'c' word Late every August, the once-and-future greats (and some not-so greats) of AIDS research pay homage to HIV co-discoverer Robert…
Studies of abacavir suggest no distinguishing benefit for abacavir compared to other currently available marketed therapies. The drug is clearly active against HIV in a variety of different patient groups; however, no evidence suggests clinically greater utility than existing nucleoside…
Third Non-Nuke Receives FDA Imprimatur and Promises to Revolutionize Triple Cocktail Mix Teratogenicity remains a concern On Friday September 18, the FDA granted accelerated approval to DuPont Pharmaceuticals' efavirenz, also known as Sustiva, a potent non-nucleoside reverse transcriptase inhibitor which…
Conference Circuit Ingénu and Self-Appointed Apothecaire Dispenses Bitter Tonic at Congress' Close Word of 'a serious malaise' As part of the "rapporteur" element of this year's world AIDS congress, 12 minute summaries of each of the four tracks (A=Basic Science;…
One Part Aged Innovation, Two Parts Hubris: Is Remune Merely Reheated '93 Berlin Fare? Memories of mock apple pie Just six months ago, when the whole eradication thing came crashing down on us like some rickety Times Square scaffolding, the…
Like last year's discovery of the gag cleavage site mutation for the protease inhibitors (which this year investigators from Virco reported to be found in up to 55% protease resistant clinical isolates), this year saw several papers reporting a 2-3…
Geneva "New Agents" Sessions Betray Dearth of Interest in Imaginative (or Costly) Drug Development Everything new is old again What is becoming clearer and clearer as these national and international meetings accumulate post-Vancouver is the need for new antiretroviral therapies…
Crypto Treatment Hopes Dashed as Sloppy, Divisive Unimed Fails to Provide Clean Data -- or Proof of Efficacy Unimed's ugly ultimatum On May 6th, the FDA’s Antiviral Drugs Advisory Committee met to consider an application for approval of Unimed Pharmaceuticals’…